EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Sutro Biopharma to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
SOUTH SAN FRANCISCO, Calif., August 10, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...
Bristol Myers Squibb Investor Series
June 25, 2020 at 11:30am ET WEBCAST View This Presentation June 22, 2020 at 11:30am ET WEBCAST View This Presentation
M1231: A First In-Class Bispecific ADC Targeting EGFR and MUC1 Presented by EMD Serono at American Association for Cancer Research (AACR) Virtual Meeting II on June 24, 2020 – Presentation
AACR requires pre-registration to access this presentation. Oral Presentation & Discussion, timestamp 1:43:36, expired link no longer available
Sutro Biopharma Presents New Preclinical Data at 2020 AACR Virtual Annual Meeting II Suggesting Synergy between its STRO-002 Antibody-Drug Conjugate and Immune Checkpoint Inhibitors Resulting in Tumor Regression and Adaptive Anti-Tumor Immunity
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 22, 2020...
Sutro Biopharma to Present New Preclinical Data on its STRO-002 Antibody-Drug Conjugate at the Upcoming AACR 2020 Virtual Meeting on June 22, 2020
Additionally, Sutro’s partner Merck KGaA, Darmstadt, Germany, will be unveiling preclinical data from the collaboration’s pre-Development Candidate, a first-in-class bispecific antibody-drug conjugate targeting EGFR and MUC1 SOUTH SAN FRANCISCO, Calif., June 9, 2020–...
Sutro Biopharma to Host Analyst and Investor Conference Call April 27, 2020 – PowerPoint Presentation
Download Presentation CLICK HERE
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
Summary of data for patients dosed at 2.9 mpk or higher in patients with heavily pre-treated ovarian cancer - 62% of patients saw a reduction in CA-125 levels of 50% or more or a normalization of CA-125 levels - 35% of patients who were evaluable for progression have...
Sutro Biopharma to Host Conference Call on April 27, 2020, to Provide Clinical Update on its STRO-002 Antibody-Drug Conjugate
-Company to present updated STRO-002 data at AACR Virtual Annual Meeting - SOUTH SAN FRANCISCO, Calif., April 20, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise...
Sutro Biopharma to Present Updated Clinical Data for its STRO-002 Antibody-Drug Conjugate at the AACR Virtual Annual Meeting on April 27, 2020
- Company to host a conference call following the presentation - SOUTH SAN FRANCISCO, Calif., April. 13, 2020 – Sutro Biopharma, Inc. (NASDAQ: STRO), today announced that the company has been invited to present updated clinical data from its STRO-002 antibody-drug...
10th Annual World ADC London 2020 – PowerPoint Presentation
To download the presentation, CLICK HERE